Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma

Sam Mayes,1 Adam Gibb,1 Tim Illidge1,21The Christie Hospital NHS Foundation, Wilmslow Road, 2School of Cancer and Enabling Sciences, University of Manchester, Manchester Academic Health Sciences Centre, UKAbstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains chall...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Illidge T, Gibb A, Mayes S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/779540bde3854435a910b61767fd764a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!